Status:
UNKNOWN
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
Lead Sponsor:
Peking University
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Brief Summary
68Ga-DOTANOC and 18F-FDG PET/CT have important values in the staging and clinical treatment of neuroendocrine tumors. Retrospective studies suggest that the positivite rates and SUVmax of dual imaging...
Eligibility Criteria
Inclusion
- sign written informed consent form
- age ≥ 18 years
- pathologically confirmed neuroendocrine, Ki67\>=10%;
- ECOG 0-1;
- No prior antitumor treatment with chemotherapy targeting regimens for neuroendocrine carcimomas, no more than 2 systematic treatment for neuroendocrine tumors;
- Unresectable disease;
- At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan \>=20mm, spiral CT scan \>=10mm, no prior radiation to measurable lesions);
- Predicted survival \>=3 months;
- Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women;
- Sexually active males or females willing to practice contraception during the study until 30 days after end of study.
Exclusion
- In the process of antitumor therapy with effective response;
- Refuse to accept PET/CT;
- Pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study;
- Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons；
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT03288597
Start Date
September 1 2017
End Date
September 1 2020
Last Update
September 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142